Third-line Treatment of Gefitinib in NSCLC Patients
Status:
Completed
Trial end date:
2018-04-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the disease control rate (DCR) of gefitinib as
third-line retreatment in stage IIIB/IV NSCLC with EGFR 19del/L858R positive mutation
patients who had benefited from first-line gefitinib treatment with EGFR 19del/L858R positive
mutation and tumor progression after the second-line chemotherapy